Castle Biosciences (CSTL) Change in Receivables (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Change in Receivables data on file, last reported at -$1.1 million in Q1 2026.

• Quarterly Change in Receivables fell 120.61% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.2 million (down 196.84% YoY) and the FY2025 annual result came in at -$6.9 million, down 154.39% from the prior year.
• Change in Receivables improved to -$1.1 million in Q1 2026 per CSTL's latest filing, from -$6.3 million in the prior quarter.
• The five-year high for Change in Receivables was $5.8 million in Q3 2023, with the low at -$6.3 million in Q4 2025.
• Average Change in Receivables over 5 years is $1.5 million, with a median of $2.7 million recorded in 2022.
• Year-over-year, Change in Receivables jumped 11502.0% in 2023 and sank 915.6% in 2025.
• Castle Biosciences' Change in Receivables stood at $540000.0 in 2022, then surged by 113.15% to $1.2 million in 2023, then slumped by 33.19% to $769000.0 in 2024, then slumped by 915.6% to -$6.3 million in 2025, then surged by 82.86% to -$1.1 million in 2026.
• Business Quant data shows CSTL's Change in Receivables at -$1.1 million in Q1 2026, -$6.3 million in Q4 2025, and -$1.9 million in Q3 2025.